Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prednisolone and methylprednisolone are both synthetic corticosteroids used primarily for their anti-inflammatory and immunosuppressive properties. They act by binding to glucocorticoid receptors, modulating gene expression, and suppressing the production of pro-inflammatory cytokines and mediators. Methylprednisolone is a methylated derivative of prednisolone, making it slightly more potent. Both drugs are indicated for a wide range of conditions including autoimmune diseases (such as rheumatoid arthritis and lupus), allergic reactions, asthma, severe skin disorders (like eczema and psoriasis), multiple sclerosis exacerbations, colitis, endocrine disorders, and more. Methylprednisolone is available in oral tablet form as well as injectable preparations for rapid or localized effect; prednisolone is typically administered orally[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prednisolone or methylprednisolone.